Last three patients enrolled into the Phase II COBALT trial on the new dosing regimen (45 mg per Day) saw a more rapid decline in LDH than those in the original …
Akari Therapeutics Announces Pricing of Public Offering of American Depositary Shares
NEW YORK and LONDON (GLOBE NEWSWIRE) October 18, 2017 / Akari Therapeutics, Plc (NASDAQ: AKTX), a biopharmaceutical company focused on the development and …
Akari Therapeutics Announces Proposed Public Offering of American Depositary Shares
NEW YORK and LONDON, October 17, 2017 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (NASDAQ: AKTX), a biopharmaceutical company focused on the development and …
Akari Therapeutics Announces Regulatory Progress Following FDA Meeting
Plans to start Coversin Phase III in PNH in Q1 2018 NEW YORK and LONDON, September 21, 2017 (GLOBE NEWSWIRE) -- Akari Therapeutics (NASDAQ: AKTX), a …
[Read more...] about Akari Therapeutics Announces Regulatory Progress Following FDA Meeting
Akari Therapeutics to Present at the Cantor Fitzgerald Global Healthcare Conference
NEW YORK and LONDON, September 19, 2017 – Akari Therapeutics (NASDAQ:AKTX), an emerging growth, clinical-stage biopharmaceutical company, is pleased to announce …
